nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—CYP1A2—Dacarbazine—pancreatic cancer	0.154	0.327	CbGbCtD
Anagrelide—CYP1A2—Tamoxifen—pancreatic cancer	0.122	0.26	CbGbCtD
Anagrelide—CYP1A2—Erlotinib—pancreatic cancer	0.104	0.221	CbGbCtD
Anagrelide—CYP1A2—Fluorouracil—pancreatic cancer	0.09	0.192	CbGbCtD
Anagrelide—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000332	0.000626	CcSEcCtD
Anagrelide—Weight increased—Epirubicin—pancreatic cancer	0.000331	0.000624	CcSEcCtD
Anagrelide—Loss of consciousness—Docetaxel—pancreatic cancer	0.00033	0.000622	CcSEcCtD
Anagrelide—Pancreatitis—Doxorubicin—pancreatic cancer	0.00033	0.000622	CcSEcCtD
Anagrelide—Weight decreased—Epirubicin—pancreatic cancer	0.000329	0.00062	CcSEcCtD
Anagrelide—Cough—Docetaxel—pancreatic cancer	0.000328	0.000618	CcSEcCtD
Anagrelide—Angina pectoris—Doxorubicin—pancreatic cancer	0.000328	0.000618	CcSEcCtD
Anagrelide—Pneumonia—Epirubicin—pancreatic cancer	0.000326	0.000615	CcSEcCtD
Anagrelide—Convulsion—Docetaxel—pancreatic cancer	0.000325	0.000613	CcSEcCtD
Anagrelide—Hypertension—Docetaxel—pancreatic cancer	0.000324	0.000611	CcSEcCtD
Anagrelide—Bronchitis—Doxorubicin—pancreatic cancer	0.000323	0.00061	CcSEcCtD
Anagrelide—Chest pain—Docetaxel—pancreatic cancer	0.00032	0.000603	CcSEcCtD
Anagrelide—Myalgia—Docetaxel—pancreatic cancer	0.00032	0.000603	CcSEcCtD
Anagrelide—Arthralgia—Docetaxel—pancreatic cancer	0.00032	0.000603	CcSEcCtD
Anagrelide—Nausea—Sunitinib—pancreatic cancer	0.00032	0.000603	CcSEcCtD
Anagrelide—Pancytopenia—Doxorubicin—pancreatic cancer	0.000319	0.000602	CcSEcCtD
Anagrelide—Renal failure—Epirubicin—pancreatic cancer	0.000319	0.000601	CcSEcCtD
Anagrelide—Asthenia—Irinotecan—pancreatic cancer	0.000318	0.0006	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000318	0.000599	CcSEcCtD
Anagrelide—Conjunctivitis—Epirubicin—pancreatic cancer	0.000315	0.000594	CcSEcCtD
Anagrelide—Urinary tract infection—Epirubicin—pancreatic cancer	0.000315	0.000594	CcSEcCtD
Anagrelide—Dysuria—Doxorubicin—pancreatic cancer	0.000315	0.000593	CcSEcCtD
Anagrelide—Dry mouth—Docetaxel—pancreatic cancer	0.000313	0.000589	CcSEcCtD
Anagrelide—Sweating—Epirubicin—pancreatic cancer	0.000311	0.000586	CcSEcCtD
Anagrelide—Pollakiuria—Doxorubicin—pancreatic cancer	0.000311	0.000586	CcSEcCtD
Anagrelide—Asthenia—Gemcitabine—pancreatic cancer	0.00031	0.000584	CcSEcCtD
Anagrelide—Haematuria—Epirubicin—pancreatic cancer	0.000309	0.000583	CcSEcCtD
Anagrelide—Confusional state—Docetaxel—pancreatic cancer	0.000309	0.000583	CcSEcCtD
Anagrelide—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000307	0.000579	CcSEcCtD
Anagrelide—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000307	0.000578	CcSEcCtD
Anagrelide—Oedema—Docetaxel—pancreatic cancer	0.000306	0.000578	CcSEcCtD
Anagrelide—Weight increased—Doxorubicin—pancreatic cancer	0.000306	0.000577	CcSEcCtD
Anagrelide—Epistaxis—Epirubicin—pancreatic cancer	0.000306	0.000576	CcSEcCtD
Anagrelide—Pruritus—Gemcitabine—pancreatic cancer	0.000306	0.000576	CcSEcCtD
Anagrelide—Infection—Docetaxel—pancreatic cancer	0.000304	0.000574	CcSEcCtD
Anagrelide—Weight decreased—Doxorubicin—pancreatic cancer	0.000304	0.000574	CcSEcCtD
Anagrelide—Sinusitis—Epirubicin—pancreatic cancer	0.000304	0.000573	CcSEcCtD
Anagrelide—Diarrhoea—Irinotecan—pancreatic cancer	0.000303	0.000572	CcSEcCtD
Anagrelide—Pneumonia—Doxorubicin—pancreatic cancer	0.000302	0.000569	CcSEcCtD
Anagrelide—Shock—Docetaxel—pancreatic cancer	0.000302	0.000568	CcSEcCtD
Anagrelide—Nervous system disorder—Docetaxel—pancreatic cancer	0.000301	0.000567	CcSEcCtD
Anagrelide—Pruritus—Fluorouracil—pancreatic cancer	0.0003	0.000566	CcSEcCtD
Anagrelide—Thrombocytopenia—Docetaxel—pancreatic cancer	0.0003	0.000566	CcSEcCtD
Anagrelide—Tachycardia—Docetaxel—pancreatic cancer	0.000299	0.000564	CcSEcCtD
Anagrelide—Skin disorder—Docetaxel—pancreatic cancer	0.000298	0.000561	CcSEcCtD
Anagrelide—Diarrhoea—Gemcitabine—pancreatic cancer	0.000295	0.000557	CcSEcCtD
Anagrelide—Renal failure—Doxorubicin—pancreatic cancer	0.000295	0.000556	CcSEcCtD
Anagrelide—Dizziness—Irinotecan—pancreatic cancer	0.000293	0.000553	CcSEcCtD
Anagrelide—Haemoglobin—Epirubicin—pancreatic cancer	0.000292	0.000551	CcSEcCtD
Anagrelide—Anorexia—Docetaxel—pancreatic cancer	0.000292	0.000551	CcSEcCtD
Anagrelide—Rhinitis—Epirubicin—pancreatic cancer	0.000292	0.00055	CcSEcCtD
Anagrelide—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000292	0.00055	CcSEcCtD
Anagrelide—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000292	0.00055	CcSEcCtD
Anagrelide—Haemorrhage—Epirubicin—pancreatic cancer	0.000291	0.000549	CcSEcCtD
Anagrelide—Hepatitis—Epirubicin—pancreatic cancer	0.000291	0.000549	CcSEcCtD
Anagrelide—Diarrhoea—Fluorouracil—pancreatic cancer	0.000291	0.000548	CcSEcCtD
Anagrelide—Hypoaesthesia—Epirubicin—pancreatic cancer	0.00029	0.000546	CcSEcCtD
Anagrelide—Pharyngitis—Epirubicin—pancreatic cancer	0.000289	0.000544	CcSEcCtD
Anagrelide—Sweating—Doxorubicin—pancreatic cancer	0.000288	0.000542	CcSEcCtD
Anagrelide—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000287	0.000542	CcSEcCtD
Anagrelide—Oedema peripheral—Epirubicin—pancreatic cancer	0.000287	0.00054	CcSEcCtD
Anagrelide—Hypotension—Docetaxel—pancreatic cancer	0.000286	0.00054	CcSEcCtD
Anagrelide—Haematuria—Doxorubicin—pancreatic cancer	0.000286	0.000539	CcSEcCtD
Anagrelide—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000286	0.000539	CcSEcCtD
Anagrelide—Urethral disorder—Epirubicin—pancreatic cancer	0.000285	0.000538	CcSEcCtD
Anagrelide—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000284	0.000535	CcSEcCtD
Anagrelide—Epistaxis—Doxorubicin—pancreatic cancer	0.000283	0.000533	CcSEcCtD
Anagrelide—Vomiting—Irinotecan—pancreatic cancer	0.000282	0.000531	CcSEcCtD
Anagrelide—Sinusitis—Doxorubicin—pancreatic cancer	0.000281	0.00053	CcSEcCtD
Anagrelide—Dizziness—Fluorouracil—pancreatic cancer	0.000281	0.000529	CcSEcCtD
Anagrelide—Visual impairment—Epirubicin—pancreatic cancer	0.00028	0.000529	CcSEcCtD
Anagrelide—Rash—Irinotecan—pancreatic cancer	0.00028	0.000527	CcSEcCtD
Anagrelide—Dermatitis—Irinotecan—pancreatic cancer	0.000279	0.000527	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000279	0.000526	CcSEcCtD
Anagrelide—Headache—Irinotecan—pancreatic cancer	0.000278	0.000524	CcSEcCtD
Anagrelide—Insomnia—Docetaxel—pancreatic cancer	0.000277	0.000523	CcSEcCtD
Anagrelide—Paraesthesia—Docetaxel—pancreatic cancer	0.000275	0.000519	CcSEcCtD
Anagrelide—Vomiting—Gemcitabine—pancreatic cancer	0.000275	0.000518	CcSEcCtD
Anagrelide—Dyspnoea—Docetaxel—pancreatic cancer	0.000273	0.000515	CcSEcCtD
Anagrelide—Somnolence—Docetaxel—pancreatic cancer	0.000272	0.000514	CcSEcCtD
Anagrelide—Rash—Gemcitabine—pancreatic cancer	0.000272	0.000513	CcSEcCtD
Anagrelide—Dermatitis—Gemcitabine—pancreatic cancer	0.000272	0.000513	CcSEcCtD
Anagrelide—Eye disorder—Epirubicin—pancreatic cancer	0.000272	0.000513	CcSEcCtD
Anagrelide—Tinnitus—Epirubicin—pancreatic cancer	0.000271	0.000511	CcSEcCtD
Anagrelide—Haemoglobin—Doxorubicin—pancreatic cancer	0.000271	0.00051	CcSEcCtD
Anagrelide—Headache—Gemcitabine—pancreatic cancer	0.000271	0.00051	CcSEcCtD
Anagrelide—Cardiac disorder—Epirubicin—pancreatic cancer	0.00027	0.000509	CcSEcCtD
Anagrelide—Vomiting—Fluorouracil—pancreatic cancer	0.00027	0.000509	CcSEcCtD
Anagrelide—Rhinitis—Doxorubicin—pancreatic cancer	0.00027	0.000509	CcSEcCtD
Anagrelide—Dyspepsia—Docetaxel—pancreatic cancer	0.00027	0.000509	CcSEcCtD
Anagrelide—Haemorrhage—Doxorubicin—pancreatic cancer	0.000269	0.000508	CcSEcCtD
Anagrelide—Hepatitis—Doxorubicin—pancreatic cancer	0.000269	0.000508	CcSEcCtD
Anagrelide—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000268	0.000505	CcSEcCtD
Anagrelide—Rash—Fluorouracil—pancreatic cancer	0.000268	0.000505	CcSEcCtD
Anagrelide—Dermatitis—Fluorouracil—pancreatic cancer	0.000267	0.000504	CcSEcCtD
Anagrelide—Pharyngitis—Doxorubicin—pancreatic cancer	0.000267	0.000504	CcSEcCtD
Anagrelide—Decreased appetite—Docetaxel—pancreatic cancer	0.000266	0.000502	CcSEcCtD
Anagrelide—Headache—Fluorouracil—pancreatic cancer	0.000266	0.000502	CcSEcCtD
Anagrelide—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000266	0.000501	CcSEcCtD
Anagrelide—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000265	0.0005	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000265	0.000499	CcSEcCtD
Anagrelide—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000265	0.000499	CcSEcCtD
Anagrelide—Fatigue—Docetaxel—pancreatic cancer	0.000264	0.000498	CcSEcCtD
Anagrelide—Urethral disorder—Doxorubicin—pancreatic cancer	0.000264	0.000498	CcSEcCtD
Anagrelide—Nausea—Irinotecan—pancreatic cancer	0.000263	0.000496	CcSEcCtD
Anagrelide—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000262	0.000494	CcSEcCtD
Anagrelide—Pain—Docetaxel—pancreatic cancer	0.000262	0.000494	CcSEcCtD
Anagrelide—Constipation—Docetaxel—pancreatic cancer	0.000262	0.000494	CcSEcCtD
Anagrelide—Chills—Epirubicin—pancreatic cancer	0.000261	0.000492	CcSEcCtD
Anagrelide—Arrhythmia—Epirubicin—pancreatic cancer	0.00026	0.00049	CcSEcCtD
Anagrelide—Visual impairment—Doxorubicin—pancreatic cancer	0.000259	0.000489	CcSEcCtD
Anagrelide—Alopecia—Epirubicin—pancreatic cancer	0.000257	0.000485	CcSEcCtD
Anagrelide—Nausea—Gemcitabine—pancreatic cancer	0.000257	0.000484	CcSEcCtD
Anagrelide—Malnutrition—Epirubicin—pancreatic cancer	0.000253	0.000478	CcSEcCtD
Anagrelide—Feeling abnormal—Docetaxel—pancreatic cancer	0.000253	0.000476	CcSEcCtD
Anagrelide—Nausea—Fluorouracil—pancreatic cancer	0.000252	0.000476	CcSEcCtD
Anagrelide—Eye disorder—Doxorubicin—pancreatic cancer	0.000252	0.000474	CcSEcCtD
Anagrelide—Tinnitus—Doxorubicin—pancreatic cancer	0.000251	0.000473	CcSEcCtD
Anagrelide—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000251	0.000472	CcSEcCtD
Anagrelide—Cardiac disorder—Doxorubicin—pancreatic cancer	0.00025	0.000471	CcSEcCtD
Anagrelide—Flatulence—Epirubicin—pancreatic cancer	0.00025	0.000471	CcSEcCtD
Anagrelide—Tension—Epirubicin—pancreatic cancer	0.000249	0.000469	CcSEcCtD
Anagrelide—Nervousness—Epirubicin—pancreatic cancer	0.000246	0.000464	CcSEcCtD
Anagrelide—Back pain—Epirubicin—pancreatic cancer	0.000245	0.000462	CcSEcCtD
Anagrelide—Muscle spasms—Epirubicin—pancreatic cancer	0.000244	0.000459	CcSEcCtD
Anagrelide—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000243	0.000457	CcSEcCtD
Anagrelide—Abdominal pain—Docetaxel—pancreatic cancer	0.000242	0.000457	CcSEcCtD
Anagrelide—Body temperature increased—Docetaxel—pancreatic cancer	0.000242	0.000457	CcSEcCtD
Anagrelide—Chills—Doxorubicin—pancreatic cancer	0.000242	0.000455	CcSEcCtD
Anagrelide—Arrhythmia—Doxorubicin—pancreatic cancer	0.000241	0.000453	CcSEcCtD
Anagrelide—Vision blurred—Epirubicin—pancreatic cancer	0.000239	0.00045	CcSEcCtD
Anagrelide—Alopecia—Doxorubicin—pancreatic cancer	0.000238	0.000449	CcSEcCtD
Anagrelide—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000235	0.000443	CcSEcCtD
Anagrelide—Malnutrition—Doxorubicin—pancreatic cancer	0.000234	0.000442	CcSEcCtD
Anagrelide—Anaemia—Epirubicin—pancreatic cancer	0.000234	0.000441	CcSEcCtD
Anagrelide—Flatulence—Doxorubicin—pancreatic cancer	0.000231	0.000435	CcSEcCtD
Anagrelide—Tension—Doxorubicin—pancreatic cancer	0.00023	0.000434	CcSEcCtD
Anagrelide—Malaise—Epirubicin—pancreatic cancer	0.000228	0.000431	CcSEcCtD
Anagrelide—Nervousness—Doxorubicin—pancreatic cancer	0.000228	0.000429	CcSEcCtD
Anagrelide—Syncope—Epirubicin—pancreatic cancer	0.000227	0.000428	CcSEcCtD
Anagrelide—Back pain—Doxorubicin—pancreatic cancer	0.000227	0.000427	CcSEcCtD
Anagrelide—Muscle spasms—Doxorubicin—pancreatic cancer	0.000225	0.000425	CcSEcCtD
Anagrelide—Palpitations—Epirubicin—pancreatic cancer	0.000224	0.000422	CcSEcCtD
Anagrelide—Loss of consciousness—Epirubicin—pancreatic cancer	0.000223	0.00042	CcSEcCtD
Anagrelide—Cough—Epirubicin—pancreatic cancer	0.000221	0.000417	CcSEcCtD
Anagrelide—Vision blurred—Doxorubicin—pancreatic cancer	0.000221	0.000416	CcSEcCtD
Anagrelide—Asthenia—Docetaxel—pancreatic cancer	0.00022	0.000415	CcSEcCtD
Anagrelide—Convulsion—Epirubicin—pancreatic cancer	0.000219	0.000414	CcSEcCtD
Anagrelide—Hypertension—Epirubicin—pancreatic cancer	0.000219	0.000412	CcSEcCtD
Anagrelide—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000217	0.00041	CcSEcCtD
Anagrelide—Pruritus—Docetaxel—pancreatic cancer	0.000217	0.000409	CcSEcCtD
Anagrelide—Anaemia—Doxorubicin—pancreatic cancer	0.000217	0.000408	CcSEcCtD
Anagrelide—Myalgia—Epirubicin—pancreatic cancer	0.000216	0.000407	CcSEcCtD
Anagrelide—Chest pain—Epirubicin—pancreatic cancer	0.000216	0.000407	CcSEcCtD
Anagrelide—Arthralgia—Epirubicin—pancreatic cancer	0.000216	0.000407	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000214	0.000404	CcSEcCtD
Anagrelide—Discomfort—Epirubicin—pancreatic cancer	0.000213	0.000402	CcSEcCtD
Anagrelide—Malaise—Doxorubicin—pancreatic cancer	0.000211	0.000398	CcSEcCtD
Anagrelide—Dry mouth—Epirubicin—pancreatic cancer	0.000211	0.000398	CcSEcCtD
Anagrelide—Syncope—Doxorubicin—pancreatic cancer	0.00021	0.000396	CcSEcCtD
Anagrelide—Diarrhoea—Docetaxel—pancreatic cancer	0.00021	0.000395	CcSEcCtD
Anagrelide—Confusional state—Epirubicin—pancreatic cancer	0.000208	0.000393	CcSEcCtD
Anagrelide—Palpitations—Doxorubicin—pancreatic cancer	0.000207	0.00039	CcSEcCtD
Anagrelide—Oedema—Epirubicin—pancreatic cancer	0.000207	0.00039	CcSEcCtD
Anagrelide—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000206	0.000388	CcSEcCtD
Anagrelide—Infection—Epirubicin—pancreatic cancer	0.000205	0.000387	CcSEcCtD
Anagrelide—Cough—Doxorubicin—pancreatic cancer	0.000205	0.000386	CcSEcCtD
Anagrelide—Shock—Epirubicin—pancreatic cancer	0.000203	0.000383	CcSEcCtD
Anagrelide—Convulsion—Doxorubicin—pancreatic cancer	0.000203	0.000383	CcSEcCtD
Anagrelide—Nervous system disorder—Epirubicin—pancreatic cancer	0.000203	0.000382	CcSEcCtD
Anagrelide—Dizziness—Docetaxel—pancreatic cancer	0.000203	0.000382	CcSEcCtD
Anagrelide—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000202	0.000382	CcSEcCtD
Anagrelide—Hypertension—Doxorubicin—pancreatic cancer	0.000202	0.000381	CcSEcCtD
Anagrelide—Tachycardia—Epirubicin—pancreatic cancer	0.000202	0.00038	CcSEcCtD
Anagrelide—Skin disorder—Epirubicin—pancreatic cancer	0.000201	0.000379	CcSEcCtD
Anagrelide—Hyperhidrosis—Epirubicin—pancreatic cancer	0.0002	0.000377	CcSEcCtD
Anagrelide—Myalgia—Doxorubicin—pancreatic cancer	0.0002	0.000376	CcSEcCtD
Anagrelide—Arthralgia—Doxorubicin—pancreatic cancer	0.0002	0.000376	CcSEcCtD
Anagrelide—Chest pain—Doxorubicin—pancreatic cancer	0.0002	0.000376	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000198	0.000374	CcSEcCtD
Anagrelide—Discomfort—Doxorubicin—pancreatic cancer	0.000197	0.000372	CcSEcCtD
Anagrelide—Anorexia—Epirubicin—pancreatic cancer	0.000197	0.000371	CcSEcCtD
Anagrelide—Dry mouth—Doxorubicin—pancreatic cancer	0.000195	0.000368	CcSEcCtD
Anagrelide—Vomiting—Docetaxel—pancreatic cancer	0.000195	0.000367	CcSEcCtD
Anagrelide—Rash—Docetaxel—pancreatic cancer	0.000193	0.000364	CcSEcCtD
Anagrelide—Hypotension—Epirubicin—pancreatic cancer	0.000193	0.000364	CcSEcCtD
Anagrelide—Dermatitis—Docetaxel—pancreatic cancer	0.000193	0.000364	CcSEcCtD
Anagrelide—Confusional state—Doxorubicin—pancreatic cancer	0.000193	0.000364	CcSEcCtD
Anagrelide—Headache—Docetaxel—pancreatic cancer	0.000192	0.000362	CcSEcCtD
Anagrelide—Oedema—Doxorubicin—pancreatic cancer	0.000191	0.000361	CcSEcCtD
Anagrelide—Infection—Doxorubicin—pancreatic cancer	0.00019	0.000358	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000188	0.000355	CcSEcCtD
Anagrelide—Shock—Doxorubicin—pancreatic cancer	0.000188	0.000355	CcSEcCtD
Anagrelide—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000188	0.000354	CcSEcCtD
Anagrelide—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000187	0.000353	CcSEcCtD
Anagrelide—Insomnia—Epirubicin—pancreatic cancer	0.000187	0.000352	CcSEcCtD
Anagrelide—Tachycardia—Doxorubicin—pancreatic cancer	0.000187	0.000352	CcSEcCtD
Anagrelide—Skin disorder—Doxorubicin—pancreatic cancer	0.000186	0.00035	CcSEcCtD
Anagrelide—Paraesthesia—Epirubicin—pancreatic cancer	0.000186	0.00035	CcSEcCtD
Anagrelide—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000185	0.000349	CcSEcCtD
Anagrelide—Dyspnoea—Epirubicin—pancreatic cancer	0.000184	0.000347	CcSEcCtD
Anagrelide—Somnolence—Epirubicin—pancreatic cancer	0.000184	0.000346	CcSEcCtD
Anagrelide—Anorexia—Doxorubicin—pancreatic cancer	0.000182	0.000344	CcSEcCtD
Anagrelide—Nausea—Docetaxel—pancreatic cancer	0.000182	0.000343	CcSEcCtD
Anagrelide—Dyspepsia—Epirubicin—pancreatic cancer	0.000182	0.000343	CcSEcCtD
Anagrelide—Decreased appetite—Epirubicin—pancreatic cancer	0.00018	0.000339	CcSEcCtD
Anagrelide—Hypotension—Doxorubicin—pancreatic cancer	0.000179	0.000337	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000178	0.000336	CcSEcCtD
Anagrelide—Fatigue—Epirubicin—pancreatic cancer	0.000178	0.000336	CcSEcCtD
Anagrelide—Pain—Epirubicin—pancreatic cancer	0.000177	0.000333	CcSEcCtD
Anagrelide—Constipation—Epirubicin—pancreatic cancer	0.000177	0.000333	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000174	0.000329	CcSEcCtD
Anagrelide—Insomnia—Doxorubicin—pancreatic cancer	0.000173	0.000326	CcSEcCtD
Anagrelide—Paraesthesia—Doxorubicin—pancreatic cancer	0.000172	0.000324	CcSEcCtD
Anagrelide—Dyspnoea—Doxorubicin—pancreatic cancer	0.000171	0.000321	CcSEcCtD
Anagrelide—Feeling abnormal—Epirubicin—pancreatic cancer	0.00017	0.000321	CcSEcCtD
Anagrelide—Somnolence—Doxorubicin—pancreatic cancer	0.00017	0.000321	CcSEcCtD
Anagrelide—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000169	0.000319	CcSEcCtD
Anagrelide—Dyspepsia—Doxorubicin—pancreatic cancer	0.000168	0.000317	CcSEcCtD
Anagrelide—Decreased appetite—Doxorubicin—pancreatic cancer	0.000166	0.000313	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000165	0.000311	CcSEcCtD
Anagrelide—Fatigue—Doxorubicin—pancreatic cancer	0.000165	0.000311	CcSEcCtD
Anagrelide—Urticaria—Epirubicin—pancreatic cancer	0.000164	0.00031	CcSEcCtD
Anagrelide—Pain—Doxorubicin—pancreatic cancer	0.000164	0.000308	CcSEcCtD
Anagrelide—Constipation—Doxorubicin—pancreatic cancer	0.000164	0.000308	CcSEcCtD
Anagrelide—Abdominal pain—Epirubicin—pancreatic cancer	0.000163	0.000308	CcSEcCtD
Anagrelide—Body temperature increased—Epirubicin—pancreatic cancer	0.000163	0.000308	CcSEcCtD
Anagrelide—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000158	0.000297	CcSEcCtD
Anagrelide—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000156	0.000295	CcSEcCtD
Anagrelide—Urticaria—Doxorubicin—pancreatic cancer	0.000152	0.000286	CcSEcCtD
Anagrelide—Body temperature increased—Doxorubicin—pancreatic cancer	0.000151	0.000285	CcSEcCtD
Anagrelide—Abdominal pain—Doxorubicin—pancreatic cancer	0.000151	0.000285	CcSEcCtD
Anagrelide—Asthenia—Epirubicin—pancreatic cancer	0.000148	0.00028	CcSEcCtD
Anagrelide—Pruritus—Epirubicin—pancreatic cancer	0.000146	0.000276	CcSEcCtD
Anagrelide—Diarrhoea—Epirubicin—pancreatic cancer	0.000141	0.000267	CcSEcCtD
Anagrelide—Asthenia—Doxorubicin—pancreatic cancer	0.000137	0.000259	CcSEcCtD
Anagrelide—Dizziness—Epirubicin—pancreatic cancer	0.000137	0.000258	CcSEcCtD
Anagrelide—Pruritus—Doxorubicin—pancreatic cancer	0.000135	0.000255	CcSEcCtD
Anagrelide—Vomiting—Epirubicin—pancreatic cancer	0.000131	0.000248	CcSEcCtD
Anagrelide—Diarrhoea—Doxorubicin—pancreatic cancer	0.000131	0.000247	CcSEcCtD
Anagrelide—Rash—Epirubicin—pancreatic cancer	0.00013	0.000246	CcSEcCtD
Anagrelide—Dermatitis—Epirubicin—pancreatic cancer	0.00013	0.000246	CcSEcCtD
Anagrelide—Headache—Epirubicin—pancreatic cancer	0.00013	0.000244	CcSEcCtD
Anagrelide—Dizziness—Doxorubicin—pancreatic cancer	0.000126	0.000238	CcSEcCtD
Anagrelide—Nausea—Epirubicin—pancreatic cancer	0.000123	0.000231	CcSEcCtD
Anagrelide—Vomiting—Doxorubicin—pancreatic cancer	0.000122	0.000229	CcSEcCtD
Anagrelide—Rash—Doxorubicin—pancreatic cancer	0.000121	0.000227	CcSEcCtD
Anagrelide—Dermatitis—Doxorubicin—pancreatic cancer	0.00012	0.000227	CcSEcCtD
Anagrelide—Headache—Doxorubicin—pancreatic cancer	0.00012	0.000226	CcSEcCtD
Anagrelide—Nausea—Doxorubicin—pancreatic cancer	0.000114	0.000214	CcSEcCtD
